Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections
Clicks: 111
ID: 271098
2005
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
111 views
25 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #708 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Background. Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria,
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (19 words).
Try re-searching for a better abstract.
| Reference Key |
e.2005clinicalrandomized,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jauregui, Luis E.;Babazadeh, Simon;Seltzer, Elyse;Goldberg, Lisa;Krievins, Dainis;Frederick, Mark;Krause, David;Satilovs, Igors;Endzinas, Zilvinas;Breaux, Jeffrey;O'Riordan, William; |
| Journal | clinical infectious diseases |
| Year | 2005 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.